Michael Brennan, MD
Cardiovascular Disease · Sheridan, WYNPI 1619903705
Payments from drug & device makers
What this record shows
Medtronic accounts for 83.7% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $1,906 and has fallen 83.3% since, to $317 in 2025.
Across 31 payments — averaging $85.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Edwards Lifesciences$211
- Abbott$72
- Actelion Pharmaceuticals US, Inc.$39
- Impulse Dynamics (USA) Inc.$26
- Boston Scientific$22
- plus $62 from 4 others
What the payments were for
- Travel & lodging$1,23646%
- Food & beverage$1,42354%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 20 | $2,226 |
| Edwards Lifesciences | 1 | $211 |
| Abbott | 1 | $72 |
| Actelion Pharmaceuticals US, Inc. | 2 | $39 |
| Impulse Dynamics (USA) Inc. | 1 | $26 |
| Boston Scientific | 1 | $22 |
| Novartis | 1 | $21 |
| Abiomed | 1 | $20 |
| Amgen | 1 | $12 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,659 in reported general payments places this provider in the 70th percentile of 22 cardiovascular disease providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 85 | $64,814 |
| Repatha SureclickEvolocumab | 11 | $5,929 |
| Metoprolol Succinate | 119 | $1,149 |
| Rosuvastatin Calcium | 61 | $789 |
| ClopidogrelClopidogrel Bisulfate | 61 | $718 |
| Flecainide Acetate | 29 | $522 |
| Atorvastatin Calcium | 52 | $378 |
| Lisinopril | 44 | $205 |
| Metoprolol Tartrate | 33 | $188 |
| Losartan Potassium | 28 | $183 |
| Potassium Chloride | 28 | $177 |
| Carvedilol | 45 | $172 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 12 | $146 |
| Furosemide | 49 | $143 |
| Atenolol | 14 | $112 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Sheridan
- Joseph GarciaSheridan$149
- Michel SkafCasper$15K
- David GonzalezAfton$6K
- Brian KellyPowell$4K
- Robert NovickCasper$4K
- Adrian FlutureCasper$3K
- Smitha NeerukondaCheyenne$3K
- William BrannEvanston$2K
- Thomas EdwardsCody$2K
- Allan WicksCasper$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.